Raw materials price spikes will prove costly for the life science industry
Companies such as Coloplast, Novo Nordisk, Ambu and Lundbeck will end up paying for the increasing costs of raw materials, predicts the head of equity research at Carnegie Investment Bank.
BY SOFIE HØJLUND, TRANSLATED BY DANIEL PEDERSEN
It will to be difficult for the life science industry to pass the rising raw material bill down the line to users as government purchasers are less willing to renegotiate new prices, says Head of Equity Research at Carnegie Investment Bank Niels Granholm-Leth, as reported by Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Global supply issues have ALK thinking creatively
For subscribers
